human | Q5 |
P496 | ORCID iD | 0000-0001-9417-9985 |
P734 | family name | Couch | Q16865801 |
Couch | Q16865801 | ||
Couch | Q16865801 | ||
P106 | occupation | researcher | Q1650915 |
P21 | sex or gender | male | Q6581097 |
Q36016386 | 11q13 is a susceptibility locus for hormone receptor positive breast cancer |
Q28141320 | 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes |
Q35871567 | 19p13.1 is a triple-negative-specific breast cancer susceptibility locus |
Q36021406 | 7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium |
Q37169873 | 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium |
Q40495288 | A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer |
Q59355837 | A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk |
Q36706890 | A YAC-, P1-, and cosmid-based physical map of the BRCA1 region on chromosome 17q21. |
Q28238155 | A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer |
Q36511037 | A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity |
Q92578601 | A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients |
Q112302372 | A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis |
Q63363987 | A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening |
Q57250674 | A common coding variant in CASP8 is associated with breast cancer risk |
Q35755874 | A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer |
Q35957063 | A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density |
Q44971724 | A comprehensive examination of CYP19 variation and breast density |
Q33844619 | A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches |
Q33857421 | A computational method to classify variants of uncertain significance using functional assay data with application to BRCA1 |
Q57105844 | A contemporary review of male breast cancer: current evidence and unanswered questions |
Q42607786 | A cysteine-for-arginine substitution (R614C) in the human skeletal muscle calcium release channel cosegregates with malignant hyperthermia |
Q37272982 | A genome wide linkage search for breast cancer susceptibility genes |
Q34744122 | A genome wide meta-analysis study for identification of common variation associated with breast cancer prognosis |
Q37192589 | A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication |
Q26829268 | A guide for functional analysis of BRCA1 variants of uncertain significance |
Q37619303 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium |
Q35089479 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population |
Q36435849 | A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. |
Q46944120 | A multi-centre international quality control study comparing mRNA splicing assay protocols and reporting practices from the ENIGMA consortium |
Q92711687 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis |
Q36152991 | A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers |
Q36790591 | A novel automated mammographic density measure and breast cancer risk |
Q35082982 | A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2. |
Q35870483 | A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients |
Q35832845 | A preliminary investigation of genetic counselors' information needs when receiving a variant of uncertain significance result: a mixed methods study |
Q97519331 | A rare TP53 mutation predominant in Ashkenazi Jews confers risk of multiple cancers |
Q35622910 | A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). |
Q36492194 | A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes |
Q57305942 | A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer |
Q28306747 | A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen |
Q37417780 | AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study |
Q57907595 | Abstract 1291: High and moderate penetrance germline mutations in a number of genes are responsible for a small proportion of familial breast cancer risk in BRCAx families |
Q57907601 | Abstract 2378: Harmonization of next generation sequencing data within consortia for gene discovery in familial breast cancer |
Q61948755 | Abstract 3266: Expression quantitative trait locus analysis of triple negative breast cancer |
Q57907603 | Abstract 3282: Determination of cancer susceptibility in probands with breast and ovarian cancer |
Q64075852 | Accuracy of self-reported cancer treatment data in young breast cancer survivors |
Q57266698 | Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers |
Q39437211 | Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers |
Q40045112 | Alcohol consumption and breast tumor gene expression |
Q33924952 | Allele-specific expression in the germline of patients with familial pancreatic cancer: an unbiased approach to cancer gene discovery |
Q34581742 | Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells |
Q36073563 | An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression |
Q34623703 | An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) |
Q35618307 | An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers |
Q33641475 | Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus |
Q35681656 | Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis |
Q101410424 | Anti-mullerian hormone as a serum biomarker for risk of chemotherapy-induced amenorrhea |
Q35242849 | Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers |
Q34613673 | Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study |
Q37308298 | Assessment of functional effects of unclassified genetic variants |
Q35156876 | Assessment of hepatocyte growth factor in ovarian cancer mortality |
Q50210067 | Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches. |
Q35218520 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy |
Q28238033 | Assignment of the human gene for the alpha 1 subunit of the skeletal muscle DHP-sensitive Ca2+ channel (CACNL1A3) to chromosome 1q31-q32 |
Q89160515 | Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer |
Q45979098 | Association analysis identifies 65 new breast cancer risk loci. |
Q33828680 | Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival |
Q37292963 | Association of ESR1 gene tagging SNPs with breast cancer risk |
Q91271723 | Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness |
Q36072765 | Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study |
Q34064603 | Association of Peutz-Jeghers-like mucocutaneous pigmentation with breast and gynecologic carcinomas in women |
Q37588396 | Association of a HOXB13 variant with breast cancer |
Q36178189 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. |
Q37684672 | Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. |
Q35640794 | Association of breast cancer susceptibility variants with risk of pancreatic cancer |
Q80428410 | Association of childhood and adolescent anthropometric factors, physical activity, and diet with adult mammographic breast density |
Q37268494 | Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry |
Q34809698 | Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer |
Q37485135 | Association of genetic variation in mitotic kinases with breast cancer risk |
Q114182713 | Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment |
Q24647329 | Association of mitotic regulation pathway polymorphisms with pancreatic cancer risk and outcome |
Q34135443 | Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality |
Q34801008 | Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
Q35957703 | Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer |
Q46782579 | Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer |
Q35022847 | Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies |
Q35523236 | Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers |
Q35532898 | Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium |
Q57056093 | Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis |
Q36085073 | Automated discovery of drug treatment patterns for endocrine therapy of breast cancer within an electronic medical record |
Q60933652 | BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2 |
Q35350825 | BRCA1 Circos: a visualisation resource for functional analysis of missense variants |
Q58289900 | BRCA1 Facilitates Stress-induced Apoptosis in Breast and Ovarian Cancer Cell Lines |
Q37261138 | BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk |
Q64039257 | BRCA1 and BRCA2 Pathogenic Sequence Variants in Women of African Origin or Ancestry |
Q37220433 | BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance |
Q53412145 | BRCA1 and BRCA2 have a limited role in familial prostate cancer. |
Q57903126 | BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic |
Q73328358 | BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer |
Q74449619 | BRCA1 testing--advances and retreats |
Q56968709 | BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study |
Q36871668 | BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management |
Q38914005 | BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer |
Q37002955 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers |
Q35079926 | BRCA2 and pancreatic cancer |
Q71167609 | BRCA2 germline mutations in male breast cancer cases and breast cancer families |
Q30524187 | BRCA2 localization to the midbody by filamin A regulates cep55 signaling and completion of cytokinesis |
Q36763221 | Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer |
Q51715408 | Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. |
Q46115524 | Body mass index and breast cancer survival: a Mendelian randomization analysis |
Q100457582 | Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk |
Q35925255 | Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers |
Q34327945 | Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2 |
Q35940158 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. |
Q57305977 | Breast-Cancer Risk in Families With Mutations in PALB2 |
Q34148873 | Breast-cancer risk in families with mutations in PALB2 |
Q100430759 | Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation |
Q43073231 | CBP truncating mutations in ovarian cancer |
Q36449203 | CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer |
Q36998293 | COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration |
Q101210788 | CRM1 inhibitor anti-tumor activity is enhanced with salicylates by S-phase arrest and impaired DNA-damage repair |
Q36419325 | CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer |
Q34793437 | CYP2B6*6 is associated with increased breast cancer risk |
Q92005489 | Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families |
Q82606196 | Cancer risk assessment at the atomic level |
Q90907699 | Cancer susceptibility gene mutations in type I and II endometrial cancer |
Q57907575 | Cancer susceptibility mutations in individuals with breast and ovarian cancer using next-generation sequencing |
Q34963894 | Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
Q28385765 | Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk |
Q52677836 | Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers. |
Q37401482 | Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis |
Q35693892 | Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci |
Q34380497 | Centrosome-related genes, genetic variation, and risk of breast cancer |
Q72148601 | Characterization of 10 new polymorphic dinucleotide repeats and generation of a high-density microsatellite-based physical map of the BRCA1 region of chromosome 17q21 |
Q24320346 | Characterization of EZH1, a human homolog of Drosophila Enhancer of zeste near BRCA1 |
Q96962174 | Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) |
Q71140973 | Chromosomal mapping of the rat Slc4a family of anion exchanger genes, Ae1, Ae2, and Ae3 |
Q73798662 | Cigarette smoking increases risk for breast cancer in high-risk breast cancer families |
Q30485153 | Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs. |
Q92097410 | Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort |
Q30373569 | Classifying Variants of Undetermined Significance in BRCA2 with protein likelihood ratios. |
Q50513952 | Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes. |
Q33779220 | Clinical options for women at high risk for breast cancer |
Q55210447 | Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices. |
Q90036958 | Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels |
Q37117082 | Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance |
Q30992909 | Collaborative science in the next-generation sequencing era: a viewpoint on how to combine exome sequencing data across sites to identify novel disease susceptibility genes |
Q94486442 | Combined associations of a polygenic risk score and classical risk factors with breast cancer risk |
Q37368000 | Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms |
Q47703662 | Common Genetic Variation and Breast Cancer Risk - Past, present, and future |
Q36839777 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers |
Q34394665 | Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction |
Q35889575 | Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. |
Q35891162 | Common breast cancer susceptibility loci are associated with triple-negative breast cancer |
Q36600605 | Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk |
Q24655824 | Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers |
Q33742096 | Common genetic variants and modification of penetrance of BRCA2-associated breast cancer |
Q34949394 | Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers |
Q35794653 | Common germline polymorphisms associated with breast cancer-specific survival |
Q34379032 | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium |
Q33947829 | Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers |
Q36393232 | Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers |
Q35870067 | Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
Q37434133 | Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers |
Q34792833 | Common variants in ZNF365 are associated with both mammographic density and breast cancer risk |
Q34213403 | Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers |
Q35815383 | Common variation in Nemo-like kinase is associated with risk of ovarian cancer |
Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
Q28652730 | Comparison of mRNA splicing assay protocols across multiple laboratories: recommendations for best practice in standardized clinical testing |
Q89047457 | Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models |
Q36026731 | Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer |
Q34181322 | Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer |
Q39398050 | Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing |
Q74243267 | Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening |
Q28302777 | Construction of a transcription map surrounding the BRCA1 locus of human chromosome 17 |
Q95292655 | Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women |
Q99408586 | Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome |
Q34541051 | Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. |
Q122925877 | Correction to: Survival from breast cancer in women with a BRCA2 mutation by treatment |
Q57266620 | Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer |
Q45793899 | Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. |
Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
Q91090014 | Correction: Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers |
Q33911135 | Counselling framework for moderate-penetrance cancer-susceptibility mutations |
Q30660858 | Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer |
Q89037078 | Current Approaches to Cancer Genetic Counseling Services for Spanish-Speaking Patients |
Q37000701 | Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance |
Q21144874 | DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers |
Q37685729 | DNA mismatch repair gene MSH6 implicated in determining age at natural menopause |
Q35562818 | Dense and nondense mammographic area and risk of breast cancer by age and tumor characteristics |
Q34495985 | Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity |
Q34116553 | Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis |
Q71961065 | Development of donor-derived prostate cancer in a recipient following orthotopic heart transplantation |
Q40421335 | Dinucleotide repeat polymorphism at the D10S178 locus |
Q40421342 | Dinucleotide repeat polymorphism at the D10S179 locus. |
Q40507224 | Dinucleotide repeat polymorphism at the D17S518 locus |
Q40507233 | Dinucleotide repeat polymorphism at the D8S161 locus |
Q40507238 | Dinucleotide repeat polymorphism at the RYR1 locus (19q13.1). |
Q52197882 | Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. |
Q35999183 | Disseminated Medulloblastoma in a Child with Germline BRCA2 6174delT Mutation and without Fanconi Anemia |
Q52675432 | Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics. |
Q27671621 | Dual recognition of phosphoserine and phosphotyrosine in histone variant H2A.X by DNA damage response protein MCPH1 |
Q55110745 | E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. |
Q35618857 | ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes |
Q47243157 | ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers |
Q34334131 | ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer |
Q100490147 | Effect of germline mutations in homologous recombination repair genes on overall survival of patients with pancreatic adenocarcinoma |
Q47614988 | Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers |
Q36245609 | Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers |
Q77137456 | Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers |
Q42237545 | Erratum to: Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status |
Q47157633 | Erratum: Author Correction: The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk |
Q57250672 | Erratum: Corrigendum: A common coding variant in CASP8 is associated with breast cancer risk |
Q57202568 | Erratum: Corrigendum: Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk |
Q112707371 | Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer |
Q51766497 | Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. |
Q36320751 | Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens |
Q36890898 | Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer |
Q89996790 | Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer |
Q33614244 | Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers |
Q37481884 | Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). |
Q36430014 | Evaluation of associations between common variation in mitotic regulatory pathways and risk of overall and high grade breast cancer |
Q36352389 | Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers |
Q37745041 | Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers |
Q33894527 | Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium |
Q34806825 | Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. |
Q35653910 | Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk |
Q34613604 | Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers |
Q36720821 | Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors |
Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
Q37342144 | Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation |
Q34408752 | Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer |
Q33863235 | Exploring the link between MORF4L1 and risk of breast cancer |
Q35999309 | FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor |
Q37594336 | FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium |
Q40676734 | Familial breast cancer. Approaching the isolation of a susceptibility gene |
Q40465630 | Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damage. |
Q53050181 | Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. |
Q53415457 | Fifty-year follow-up of cancer incidence in a historical cohort of Minnesota breast cancer families. |
Q37236216 | Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). |
Q36111237 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus |
Q36087170 | Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers |
Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
Q61230414 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes |
Q92480972 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes |
Q35063160 | Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk |
Q39844032 | Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer |
Q36248936 | Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk |
Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
Q37367871 | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. |
Q37002930 | Five endometrial cancer risk loci identified through genome-wide association analysis |
Q34979715 | Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium |
Q89668743 | Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients |
Q47828874 | Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. |
Q41193996 | Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families |
Q48328498 | From the laboratory to the clinic: sharing BRCA VUS reclassification tools with practicing genetics professionals |
Q91404398 | Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2 |
Q35775886 | Functional assays for BRCA1 and BRCA2. |
Q37715826 | Functional assays for analysis of variants of uncertain significance in BRCA2. |
Q34116524 | Functional assays for classification of BRCA2 variants of uncertain significance |
Q38637888 | Functional assays provide a robust tool for the clinical annotation of genetic variants of uncertain significance. |
Q90859747 | Functional characterization of 84 PALB2 variants of uncertain significance |
Q95814860 | Functional evaluation and cancer risk assessment of BRCA2 unclassified variants |
Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
Q37369575 | Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma |
Q36742577 | Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers |
Q59565524 | Gene-Expression–Based Predictors for Breast Cancer |
Q40137431 | Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium |
Q36175072 | Gene-panel sequencing and the prediction of breast-cancer risk |
Q38627916 | Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication |
Q28290206 | Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13 |
Q33589487 | Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes |
Q37389405 | Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer |
Q90089832 | Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) C |
Q34890924 | Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor |
Q53396872 | Genetic analysis of early- versus late-stage ovarian tumors. |
Q40952676 | Genetic analysis of eight breast-ovarian cancer families with suspected BRCA1 mutations |
Q35909002 | Genetic counselors' practices and confidence regarding variant of uncertain significance results and reclassification from BRCA testing |
Q35836788 | Genetic epidemiology of BRCA1. |
Q34509444 | Genetic heterogeneity in Peutz-Jeghers syndrome |
Q35882332 | Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2. |
Q108609948 | Genetic insights into biological mechanisms governing human ovarian ageing |
Q37739048 | Genetic modifiers of CHEK2*1100delC-associated breast cancer risk |
Q29417068 | Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study |
Q54940815 | Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. |
Q92349476 | Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer |
Q35925620 | Genetic predisposition to ductal carcinoma in situ of the breast |
Q35151684 | Genetic predisposition to in situ and invasive lobular carcinoma of the breast |
Q62583135 | Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma |
Q36846498 | Genetic susceptibility to triple-negative breast cancer |
Q35022825 | Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers |
Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
Q35961713 | Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers |
Q37467266 | Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers |
Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
Q37131328 | Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies |
Q37311599 | Genetic variation in the chromosome 17q23 amplicon and breast cancer risk |
Q33889494 | Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer |
Q36422109 | Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium |
Q43167965 | Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants |
Q30000080 | Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent |
Q35444584 | Genetics of the FANCA gene in familial pancreatic cancer |
Q28388497 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types |
Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
Q63681757 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer |
Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
Q29417100 | Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer |
Q95329367 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses |
Q35061252 | Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk |
Q24645441 | Genome-wide association study identifies novel breast cancer susceptibility loci |
Q27008356 | Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk |
Q64040390 | Genome-wide association study of germline variants and breast cancer-specific mortality |
Q37242239 | Genomic Biomarkers for Breast Cancer Risk |
Q59566871 | Genomic analyses for age at menarche identify 389 independent signals and indicate BMI-independent effects of puberty timing on cancer susceptibility |
Q38823212 | Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk |
Q81369409 | Germ line Fanconi anemia complementation group C mutations and pancreatic cancer |
Q92109896 | Germline Genetic Testing for Breast Cancer Risk: The Past, Present, and Future |
Q96432094 | Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk |
Q101220927 | Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk-based testing of those older than 60 years |
Q45733546 | Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women |
Q35881432 | Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study |
Q35382206 | Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers |
Q57471595 | Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study |
Q36276540 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization |
Q92568416 | Hereditary Cancer Syndromes-A Primer on Diagnosis and Management, Part 2: Gastrointestinal Cancer Syndromes |
Q92568411 | Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1: Breast-Ovarian Cancer Syndromes |
Q33330850 | Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics |
Q36547888 | Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers |
Q91571366 | Hi-Plex2: a simple and robust approach to targeted sequencing-based genetic screening |
Q37121271 | High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium |
Q78002659 | I1307K APC variant in non-Ashkenazi Jewish women affected with breast cancer |
Q57903145 | I1307K APC variant in non‐Ashkenazi Jewish women affected with breast cancer |
Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
Q37006170 | Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. |
Q37532636 | Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer |
Q30252854 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer |
Q36465306 | Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? |
Q36720814 | Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk |
Q36062033 | Identification of a novel percent mammographic density locus at 12q24. |
Q47369955 | Identification of a pyruvate-to-lactate signature in pancreatic intraductal papillary mucinous neoplasms |
Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
Q28943279 | Identification of inherited genetic variations influencing prognosis in early-onset breast cancer |
Q45952886 | Identification of molecular subtypes within a formalin-fixed, paraffin-embedded breast cancer tumour cohort. |
Q34038964 | Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions |
Q57170142 | Identification of nine new susceptibility loci for endometrial cancer |
Q36014067 | Identification of novel genetic markers of breast cancer survival |
Q35541663 | Identification of six new susceptibility loci for invasive epithelial ovarian cancer |
Q46103372 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer |
Q100957803 | Impact of Personalized Genetic Breast Cancer Risk Estimation With Polygenic Risk Scores on Preventive Endocrine Therapy Intention and Uptake |
Q91595570 | Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation |
Q50075112 | Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. |
Q39659182 | Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer |
Q34733426 | Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice |
Q114184688 | Incorporating progesterone receptor expression into the PREDICT breast prognostic model |
Q50156693 | Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. |
Q74232945 | Induction of the BRCA2 promoter by nuclear factor-kappa B |
Q37410472 | Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women |
Q34996647 | Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer |
Q57907552 | Inherited mutations in breast cancer patients with and without multiple primary cancers |
Q35104068 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer |
Q35871175 | Integrated Genomic Analysis of Pancreatic Ductal Adenocarcinomas Reveals Genomic Rearrangement Events as Significant Drivers of Disease |
Q33910123 | Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2 |
Q100762144 | Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance |
Q40155925 | Interaction of mammographic breast density with menopausal status and postmenopausal hormone use in relation to the risk of aggressive breast cancer subtypes |
Q34116505 | International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers |
Q34081324 | Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer |
Q34898735 | Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors |
Q74664770 | Is BRCA1 associated with familial breast cancer in India? |
Q64279327 | Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk |
Q47190168 | Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium |
Q92313654 | Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification |
Q57191573 | Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair |
Q28267893 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair |
Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
Q33742726 | Linkage analysis of obesity phenotypes in pre- and post-menopausal women from a United States mid-western population |
Q36564941 | Localization of BRCA1 and a splice variant identifies the nuclear localization signal |
Q77303995 | Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer |
Q72195919 | Localization of the gene for ATP citrate lyase (ACLY) distal to gastrin(GAS) and proximal to D17S856 on chromosome 17q12-q21 |
Q28277339 | Localization of the human homolog of the yeast cell division control 27 gene (CDC27) proximal to ITGB3 on human chromosome 17q21.3 |
Q36796808 | Loss of the transcription factor GLI1 identifies a signaling network in the tumor microenvironment mediating KRAS oncogene-induced transformation |
Q35119701 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium |
Q31043651 | Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. |
Q37590600 | Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results |
Q90540990 | Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century |
Q36043843 | Mammographic breast density and breast cancer: evidence of a shared genetic basis |
Q37690341 | Mammographic density and risk of breast cancer by age and tumor characteristics |
Q37476623 | Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status |
Q88572181 | Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations |
Q112283176 | Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities |
Q92860654 | Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers |
Q114182490 | Mendelian randomisation study of smoking exposure in relation to breast cancer risk |
Q36333368 | Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. |
Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
Q46470461 | Microarray based expression profiling of BRCA1 mutated human tumours using a breast-specific platform to identify a profile of BRCA1 deficiency |
Q37253346 | Microcephalin regulates BRCA2 and Rad51-associated DNA double-strand break repair |
Q34123806 | Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls |
Q35207476 | Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes |
Q37362211 | Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers |
Q27675971 | Molecular Basis for the Association of Microcephalin (MCPH1) Protein with the Cell Division Cycle Protein 27 (Cdc27) Subunit of the Anaphase-promoting Complex |
Q40052411 | Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. |
Q112642940 | Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study |
Q58546150 | Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues |
Q93190763 | Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility Genes |
Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
Q38262388 | Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer |
Q99585109 | Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers |
Q41674947 | Mutation analysis of the BRCA1 gene in ovarian cancers. |
Q95650235 | Mutation prevalence tables for hereditary cancer derived from multi-gene panel testing |
Q36162179 | Mutation screening of RAD51C in high-risk breast and ovarian cancer families |
Q72052944 | Mutation screening of dihydropyridine receptor gamma subunit cDNA from malignant hyperthermia susceptible patients |
Q49024646 | Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations. |
Q28269064 | Mutational analysis of thirty-two double-strand DNA break repair genes in breast and pancreatic cancers |
Q71532382 | Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core |
Q72640314 | Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer |
Q55670933 | Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia |
Q71148392 | Mutations of the BRCA2 gene in ovarian carcinomas |
Q37356243 | Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. |
Q33500353 | No association between a candidate TCF7L2 variant and risk of breast or ovarian cancer |
Q37237352 | No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study |
Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
Q36393107 | No evidence for association of inherited variation in genes involved in mitosis and percent mammographic density |
Q37308596 | No evidence that GATA3 rs570613 SNP modifies breast cancer risk |
Q37079859 | No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing |
Q39267728 | Non-BRCA familial breast cancer: review of reported pathology and molecular findings |
Q35752042 | Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures |
Q36886874 | Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin |
Q34172655 | Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers |
Q34705352 | On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations |
Q91524809 | Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers |
Q34162534 | Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers |
Q89927576 | Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D |
Q36280191 | Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers |
Q28584533 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS |
Q47143943 | PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1. |
Q36184231 | PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. |
Q32042292 | PS6K amplification characterizes a small subset of anaplastic meningiomas |
Q34289136 | Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche |
Q98652521 | Pathogenic Variants in Cancer Predisposition Genes and Prostate Cancer Risk in Men of African Ancestry |
Q35737888 | Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) |
Q37307937 | Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium |
Q90070074 | Patients' Medical and Psychosocial Experiences After Detection of a CDH1 Variant With Multigene Panel Testing |
Q36873786 | Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium |
Q34477526 | Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes |
Q36395163 | Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo |
Q37021548 | Poly(ADP-ribose) polymerase-1 down-regulates BRCA2 expression through the BRCA2 promoter |
Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
Q97524107 | Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants |
Q37343314 | Polymorphic variants in hereditary pancreatic cancer genes are not associated with pancreatic cancer risk |
Q35431613 | Polymorphisms in PTEN in breast cancer families |
Q36066735 | Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression |
Q34311315 | Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study |
Q33704900 | Prediction and assessment of splicing alterations: implications for clinical testing |
Q36356727 | Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores |
Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
Q94596762 | Prediction of the functional impact of missense variants in BRCA1 and BRCA2 with BRCA-ML |
Q36581642 | Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients |
Q37350137 | Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups |
Q71809714 | Progress toward Isolation of a Breast Cancer Susceptibility Gene, BRCA1 |
Q36920323 | Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging |
Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
Q90242034 | Publisher Correction: Shared heritability and functional enrichment across six solid cancers |
Q36512097 | RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies |
Q36009422 | RAD51B in Familial Breast Cancer |
Q101219539 | Racial and ethnic differences in multigene hereditary cancer panel test results for women with breast cancer |
Q30494804 | Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study |
Q36785963 | Rapid progression of prostate cancer in men with a BRCA2 mutation |
Q42672216 | Rare variants in XRCC2 as breast cancer susceptibility alleles |
Q91614061 | Real-world experiences with acupuncture among breast cancer survivors: a cross-sectional survey study |
Q92354907 | Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework |
Q35194440 | Refined genetic localization for central core disease |
Q35155449 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia |
Q89505894 | Reply to On the proportion of male breast cancer among all breast cancers |
Q45951126 | Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. |
Q57269829 | Response: Table 1 |
Q89458187 | Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Probands' Susceptibility Gene Mutation Status |
Q73062975 | Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer |
Q37300024 | Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. |
Q33527422 | Risk of ovarian cancer and inherited variants in relapse-associated genes |
Q36545934 | SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival |
Q55042194 | Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. |
Q36958682 | Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers |
Q61118451 | Shared heritability and functional enrichment across six solid cancers |
Q64004349 | Shared heritability and functional enrichment across six solid cancers |
Q35073076 | SoftSearch: integration of multiple sequence features to identify breakpoints of structural variations |
Q35121513 | Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary |
Q37246207 | Spontaneous vulvar papillomas in a colony of mice used for pancreatic cancer research. |
Q22003975 | Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells |
Q51739138 | Strong evidence of a genetic determinant for mammographic density, a major risk factor for breast cancer. |
Q74114386 | Structural analysis of the 17q22-23 amplicon identifies several independent targets of amplification in breast cancer cell lines and tumors |
Q42463910 | Subtypes of familial breast tumours revealed by expression and copy number profiling |
Q33593016 | Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies |
Q74409735 | TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors |
Q33566957 | TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer |
Q50690518 | Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. |
Q81119061 | Targeted Therapy for BRCA2 Deficient Tumors |
Q24306949 | Tex14, a Plk1-regulated protein, is required for kinetochore-microtubule attachment and regulation of the spindle assembly checkpoint |
Q35130683 | The 17q23 amplicon and breast cancer |
Q92608385 | The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network |
Q38793676 | The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium |
Q49817640 | The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. |
Q91178389 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer |
Q34115636 | The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers |
Q52673733 | The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. |
Q37578078 | The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers |
Q42371653 | The PALB2 p.Leu939Trp mutation is not associated with breast cancer risk |
Q35781316 | The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients |
Q35685546 | The association of copy number variation and percent mammographic density |
Q41226231 | The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds |
Q89856001 | The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort |
Q33784408 | The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk |
Q36137764 | The contributions of breast density and common genetic variation to breast cancer risk |
Q35608600 | The germline MLH1 K618A variant and susceptibility to Lynch syndrome-associated tumors |
Q34653100 | The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen |
Q36981617 | The influence of mammogram acquisition on the mammographic density and breast cancer association in the Mayo Mammography Health Study cohort |
Q35592084 | The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor |
Q57265642 | The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant |
Q79776058 | The prevalence of BRCA2 mutations in familial pancreatic cancer |
Q35024008 | The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing |
Q35858233 | The role of Tbx2 and Tbx3 in mammary development and tumorigenesis |
Q36142060 | The role of genetic breast cancer susceptibility variants as prognostic factors |
Q47397232 | Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach |
Q36703478 | Transcript identification in the BRCA1 candidate region |
Q89961489 | Transcriptome-wide association study of breast cancer risk by estrogen-receptor status |
Q41645489 | Transcriptomic and Immunohistochemical Profiling of SLC6A14 in Pancreatic Ductal Adenocarcinoma |
Q37325069 | Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging |
Q58797082 | Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing |
Q52574720 | Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer risk. |
Q33820594 | Two decades after BRCA: setting paradigms in personalized cancer care and prevention |
Q92994868 | Two truncating variants in FANCC and breast cancer risk |
Q34475484 | Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers |
Q38342626 | Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas |
Q90169993 | Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation |
Q34099786 | Variation at 8q24 and 9p24 and risk of epithelial ovarian cancer |
Q33636005 | Variation in genes required for normal mitosis and risk of breast cancer |
Q35041278 | Von Hippel-Lindau gene product directs cytokinesis: a new tumor suppressor function |
Q104484001 | Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer |
Q44319466 | p53 mediates repression of the BRCA2 promoter and down-regulation of BRCA2 mRNA and protein levels in response to DNA damage |
Q73351878 | p73 mutations are not detected in sporadic and hereditary breast cancer |
Q37414133 | rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk |
Search more.